Results 101 to 110 of about 7,047 (156)

Drug Discovery of Allosteric Molecular Glue Degraders (aMGDs): Expanding the Landscape of Targeted Protein Degradation. [PDF]

J Med Chem
Xue Y, Ali S, Chen H, Zhou J.
europepmc   +1 more source

Two Decades of <i>NPM1</i>-Mutated Acute Myeloid Leukemia: From Molecular Insights to Clinical Decision-Making. [PDF]

Cancers (Basel)
Cimino G, Caridi M, Celenza R, Millucci F, Crocioni M, Sciabolacci S, Cardinali V, Martelli MP.   +7 more
europepmc   +1 more source

Nuclear-Cytoplasmic Axis in Cancer: From Protein Mislocalization to Anticancer Drug Resistance. [PDF]

Oncol Res
Zhu X, He M, Wang L, Su R, Zhong L, Guo T, Wang H, Zou D.   +7 more
europepmc   +1 more source

NPM1-rearranged AML: clinical features, molecular pathogenesis, and therapeutic perspectives. [PDF]

Int J Hematol
Shimosato Y, Goyama S.
europepmc   +1 more source

Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors

Background: Advanced pancreatic neuroendocrine tumors (pNETs) show minimal response to FDA approved therapies suggesting an urgent need for the identification of novel and effective therapeutic targets. Aberrant nuclear protein transport to the cytoplasm,
Bannoura, S. F, Diab, Maria, Beal, E., Uddin, M. H, Kim, S., Dyson, G., Azmi, A. S, Beydoun, R., Pasche, B., El-Rayes, B. F, Al-Hallak, M. N, Chen, H., Khan, H. M, Mohammad, R. M, Philip, Philip A, Tobon, M.   +15 more
core   +1 more source

Nucleoporins in Cancer: Functional Roles and Therapeutic Opportunities. [PDF]

Cancer Discov
Kirthika P, Jawalagatti V, Carceles-Cordon M, Domingo-Domenech J, Rodriguez-Bravo V.   +4 more
europepmc   +1 more source

Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma. [PDF]

Cancer Med
Xu H, Wu W, Jiang Y, Wang J, Zhai Y, Zhao Z.   +5 more
europepmc   +1 more source

Exportin 1 Inhibitor Combined With Venetoclax Induces Apoptosis in Myelodysplastic Syndrome by Mitochondria-Induced Apoptosis Pathway. [PDF]

J Clin Lab Anal
Liu X, Huang L, Wang J, Guo Y, Shen H, Zhao X, Yue L, Liu Z, Fu R.   +8 more
europepmc   +1 more source

Selinexor for myelofibrosis or a drug in search of a disease? [PDF]

Blood Cancer J
Gangat N, Tefferi A.
europepmc   +1 more source

Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial. [PDF]

Oncologist
Liu C, Li D, Gao Y, Zhang W, Guo Z, Zhao J, Huang H, Tao R.   +7 more
europepmc   +1 more source